Literature DB >> 23524420

Short-term effect of zoledronic acid upon fracture resistance of the mandibular condyle and femoral head in an animal model.

Fabio Camacho-Alonso1, Pía López-Jornet, Ascensión Vicente-Hernández.   

Abstract

OBJECTIVE: The aim of this study was to compare the effects in terms of resistance to fracture of the mandibular condyle and femoral head following different doses of zoledronic acid in an animal model. STUDY
DESIGN: A total of 80 adult male Sprague-Dawley rats were included in a prospective randomized study. The animals were randomly divided into four groups of 20 rats each. Group 1 (control) received sterile saline solution, while groups 2, 3 and 4 received a accumulated dose of 0.2 mg, 0.4 mg and 0.6 mg of zoledronic acid, respectively. The animals were sacrificed 28 days after the last dose, and the right hemimandible and the right femur were removed. The fracture strength was measured (in Newtons) with a universal test machine using a 1 kN load connected to a metal rod with one end angled at 30 degrees. The cross-head speed was 1 mm/min. Later, the specimens were observed under a scanning electron microscope with backscattered electron imaging (SEM-BSE). At last, chemical analysis and elemental mapping of the mineral bone composition were generated using a microanalytical system based on energy-dispersive and X-ray spectrometry (EDX).
RESULTS: A total of 160 fracture tests were performed. The fracture resistance increased in mandible and femur with a higher accumulated dose of zoledronic acid. Statistically significant differences were recorded versus the controls with all the studies groups. The chemical analysis in mandible showed a significantly increased of calcium and phosphorous to compare the control with all of the study groups; however, in femur no statistically significant differences between the four study groups were observed.
CONCLUSIONS: The administration of bisphosphonates increases the fracture resistance in mandible and femur.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23524420      PMCID: PMC3668867          DOI: 10.4317/medoral.18449

Source DB:  PubMed          Journal:  Med Oral Patol Oral Cir Bucal        ISSN: 1698-4447


  16 in total

1.  Low bone turnover and microdamage? How and where to assess it?

Authors:  David B Burr; Matthew R Allen
Journal:  J Bone Miner Res       Date:  2008-07       Impact factor: 6.741

2.  Microcracking damage and the fracture process in relation to strain rate in human cortical bone tensile failure.

Authors:  Peter Zioupos; Ulrich Hansen; John D Currey
Journal:  J Biomech       Date:  2008-09-10       Impact factor: 2.712

Review 3.  How can bone turnover modify bone strength independent of bone mass?

Authors:  C J Hernandez
Journal:  Bone       Date:  2008-02-20       Impact factor: 4.398

Review 4.  Basic biomechanical measurements of bone: a tutorial.

Authors:  C H Turner; D B Burr
Journal:  Bone       Date:  1993 Jul-Aug       Impact factor: 4.398

5.  Treatment of bone metastasis in prostate cancer: efficacy of a novel polybisphosphonate.

Authors:  Florence Daubine; Ronan LE Bot; Marcela Márquez; Sten Nilsson; Torbjörn Schröder; Anders R Holmberg
Journal:  Anticancer Res       Date:  2011-12       Impact factor: 2.480

6.  Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs.

Authors:  M R Allen; D B Burr
Journal:  Osteoporos Int       Date:  2007-08-21       Impact factor: 4.507

Review 7.  Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?

Authors:  Ian R Reid; Mark J Bolland; Andrew B Grey
Journal:  Bone       Date:  2007-05-10       Impact factor: 4.398

Review 8.  Osteochemonecrosis of the jaws due to bisphosphonate treatments. Update.

Authors:  Rafael Gómez Font; María Luisa Martínez García; José Manuel Olmos Martínez
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2008-05-01

9.  Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat.

Authors:  Frieder Bauss; Thomas Pfister; Socrates Papapoulos
Journal:  J Bone Miner Metab       Date:  2008-07-04       Impact factor: 2.626

Review 10.  Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.

Authors:  M Aapro; P A Abrahamsson; J J Body; R E Coleman; R Colomer; L Costa; L Crinò; L Dirix; M Gnant; J Gralow; P Hadji; G N Hortobagyi; W Jonat; A Lipton; A Monnier; A H G Paterson; R Rizzoli; F Saad; B Thürlimann
Journal:  Ann Oncol       Date:  2007-09-28       Impact factor: 32.976

View more
  2 in total

1.  In vivo and in vitro analysis in a rat model using zoledronate and alendronate medication: microbiological and scanning electron microscopy findings on peri-implant rat tissue.

Authors:  Ali Al-Ahmad; Ali Modabber; Kristian Kniha; Eva Miriam Buhl; Stephan Christian Möhlhenrich; Anna Bock; Frank Hölzle; Elmar Hellwig
Journal:  BMC Oral Health       Date:  2021-12-31       Impact factor: 2.757

2.  Case report of maxillofacial fracture in a patient under bisphosphonates in the absence of ONJ disease: Guidelines?

Authors:  Philippe Van Camp; Bert Gemels; Guido Heijsters; Serge Schepers
Journal:  Int J Surg Case Rep       Date:  2018-09-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.